Results: In the original diabetic cohort, 60,969 statin users and 535,843 statin nonusers were identified. In a median follow-up time of 7.9 years, a total of 1182 incident SCC cases and 2345 adenocarcinoma cases developed. Initial analysis showed a decreased risk of SCC if statins were ever used (HR, 0.69; 95% confidence interval, 0.60e0.81). However, the relative risk would be 0.92 for males and 0.90 for females for statins after adjusting for smoking effect. There was no association between statin use and adenocarcinoma (HR, 0.97; 95% confidence interval, 0.88e1.07), with similar findings after controlling for smoking effect. Conclusion: There is no statistically significant association between statin use with lung cancer incidence in diabetic patients after adjustment for the confounding effect attributed to cigarette smoking.
KEYWORDS 3-hydroxy-3-methylglutaryl-CoA; diabetes mellitus; lung neoplasms; smoking; statins Background/Purpose: The relationship between statin use and lung cancer remains unclear. Patients with diabetes mellitus, who are at higher risks for both cancer and atherosclerosis, are usually indicated for statin use. The objective was to explore the relationship between statins, lung squamous cell carcinoma (SCC), and lung adenocarcinoma incidence in diabetic patients. Methods: A cohort of 596,812 type 2 diabetic patients was identified from the Taiwan National Health Insurance claims database in the year 2000, and followed until the earliest of lung cancer diagnosis, death, or December 31, 2007 . A Cox regression model with time-varying statin use was applied to estimate the hazard ratio (HR) of lung cancer incidence comparing use and nonuse of statins. A sensitivity analysis was applied to examine the association after adjustment for smoking effect.
Introduction
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase that have been widely used to lower serum cholesterol levels and proven for prevention of cardiovascular diseases. 1 Due to the pleiotropic effects, statins have shown potential benefits in several diseases. 2 Furthermore, given their involvement in a number of growth-regulatory processes, statins have been suggested as anticancer drugs.
However, the PROSPER and LIPID trials reported that patients taking pravastatin more often developed cancer. 3, 4 By contrast, several observational studies and meta-analysis of randomized trials did not indicate an increase in overall cancer risk for statins. 5, 6 Among all malignancies, lung cancer is one of the most common and lethal types. A retrospective case-control study demonstrated that statin use was associated with a risk reduction of lung cancer of 55%. 7 It has been argued that the beneficial effect might result from "time-window bias" because different time lengths between cases and controls are used to define time-dependent exposures. When time was accounted for properly, no benefit of statins on lung cancer risk is suggested. 8 Similarly, in cohort studies comparing those who have used statins at any time with those who have not, a follow-up period during which a study outcome cannot occur confers a spurious advantage to the treated group. 9 In case of inappropriate accounting for follow-up time and treatment status, it may introduce "immortal time bias". Other potential bias includes failure to control for important confounding factors, in particular cigarette smoking. 10 Furthermore, lung cancer comprises various cell types. Evidence suggests that lung squamous cell carcinoma (SCC) and adenocarcinoma have different risk factors and respond differently to chemotherapy or target therapy. 11, 12 Analyses examining the relation with overall lung cancer risk are likely to diminish the risk estimate if statin use is associated with only one of the cell types.
Due to the controversy, we aimed to conduct a nationwide study to illustrate the association between statin use and lung cancer incidence (SCC and adenocarcinoma), taking into account immortal time bias, in the diabetic patients, who have been regarded as a high-risk group for cancer 13, 14 and also have an indication for statin use. 15 
Materials and methods

Data source
The Taiwan National Health Insurance (NHI) claims database includes complete outpatient visits, hospital admissions, prescriptions, disease, and vital status for 99% of the population of 23 million in Taiwan. We established the longitudinal medical history of each beneficiary by linking several computerized claims datasets and National Cancer and Death Registry through the civil identification number unique to each beneficiary and birth date. The study protocol was approved by the National Taiwan University Hospital Research Ethics Committee.
Study population
Data for all patients with any diabetes diagnostic codes (The International Classification of Diseases, 9th Revision, Clinical Modification, ICD-9-CM code 250 and A code 181) in the claims database between January 1, 2000 and December 31, 2000 were retrieved. An algorithm including age, number of outpatient visits, number of hospitalizations, and the hospital level was used to identify potential diabetic patients with improved accuracy. This definition of diabetes was evaluated by a study sampling 9000 patients with a diagnosis of diabetes in the NHI claims data in 2000. The diagnostic accuracy of diabetes was assessed based on patient response to a questionnaire concerning being told by doctors to have diabetes or ever use of hypoglycemic agents. Individuals who gave negative or uncertain answers but were using hypoglycemic agents in the pharmacy claims database were also classified as diabetic. Validation of this algorithm by which 640,173 patients were identified demonstrated 93.2% sensitivity and 92.3% positive predictive value. This diabetic cohort has been studied to examine the cancer risk of several medications, including hypoglycemic agents and angiotensin receptor blockers. 16e18 To enroll patients aged 30e100 years with type 2 diabetes, we first excluded those who had insulin dependent diabetes mellitus. Patients were further classified as having prevalent or newly-diagnosed type 2 diabetes according to the criteria in 1999. Patients were followed from January 1, 2000 (for prevalent type 2 diabetes patients) or the date of diabetes diagnosis in 2000 (for newly diagnosed type 2 diabetes patients) to the earliest of cancer diagnosis, death, disenrollment from the NHI, or December 31, 2007.
Assessment of statin use
The exposure of interest was use of statins, including simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, and rosuvastatin. We collected information of prescribed drug types, dosage, prescription date, supply days, and total number of pills dispensed from the outpatient pharmacy prescription database. We also calculated cumulative treatment duration and dosage among statin users. Patients were allowed to have a grace period of up to 30 days between prescription dates when calculating continuous therapy. Data are presented as the number of defined daily doses, which was established by an expert panel as the typical maintenance daily dose for a drug prescribed for its main indication in adults. 19 
Assessment of other covariates
Other medications, including hypoglycemic agents, fibrates, low dose aspirin, and various antihypertensive drugs were recorded. Covariate information included age, sex, the socio-economic status (using monthly income as a proxy), and comorbidities.
Assessment of lung cancer
All individuals in the study cohort with first occurrence of pathologically confirmed primary lung cancer, including SCC and adenocarcinoma, were identified. All potential cases were validated and information about cell types was obtained by a linkage through the National Cancer Registry.
Statistical analysis
Demographic characteristics, comorbidities, and medication use between statin users and nonusers in 2000 were compared. For all diabetic cohort members, we computed their follow-up person-days in individual statin. Because of the time-varying nature of drug use and the potential cumulative drug effect on lung cancer incidence in a prolonged duration, we defined each participant's exposure status as "use" at the date of first statin prescription and this status remained unchanged until the end of follow-up. Participants who received no stain prescription contributed to the category of "nonuse". A Cox regression model with time-varying statin use and other covariates was used to estimate the crude and adjusted hazard ratio (HR) and 95% confidence interval (CI) for the association between "use" of statin as a class and individual statin and cancer occurrence with "nonuse" as the reference group. Because drug exposure status or cumulative dosage changes over time, the commonly propensity score matching method is highly complex to be conducted and may reduce the sample size in the matching process. Instead, the time-varying multivariate regression analysis can provide similar risk estimates and effectively prevent the immortal time bias in the setting. 9 Potential covariates were selected by stepwise selection with p < 0.10 for model entry and p > 0.05 for removal. The associations between statin use and lung SCC and adenocarcinoma incidence were separately estimated.
In the dose-and duration-response analyses, we calculated the HRs for higher, intermediate, and lower cumulative dose in terms of defined daily doses, and for cumulative treatment duration !3 years, 2e3 years, 1e2 years, and 1 year. Additionally, subgroup analyses were performed to evaluate potential effect modification. Diabetic patients were stratified according to: (1) newlydiagnosed or prevalent diabetes; (2) statin new users or prevalent users; (3) men or women; and (4) age <65 years or !65 years. A two-sided p < 0.05 was considered statistically significant.
Sensitivity analysis to assess unmeasured confounding effect by smoking using external data
The information of relevant lifestyle factors, such as smoking, altering the risk of lung cancer was usually not recorded in the NHI claims database preventing us from direct adjustment for their possible confounding effects. Therefore, to investigate the potential impact of smoking, we analyzed data from the National Health Interview Survey (NHIS) in Taiwan 2005 to quantify the imbalance in proportion of smokers between statin users and nonusers. This was a cross-sectional survey of a national representative sample based on a multistage complex design. 20 The survey was conducted by trained interviewers under a standardized protocol and included demographic characteristics, health status and behavior, medical utilization, and other relevant information. A total of 27,726 participants completed the survey with the response rate of 80.6%. Participants were defined as having diabetes if they reported that they had been told by a doctor or healthcare professional that they had diabetes. Question items of whether the interviewees are currently receiving lipidlowering medication and their smoking history were used to calculate prevalence of smoking status (ever, never) in statin users and nonusers. We further conducted quantitative sensitivity analysis to understand how the strength of an unmeasured confounder, i.e., smoking status in this study, and imbalance among statin users and nonusers affects the observed association. 21 Because the relationship of smoking and lung cancer varies with ethnicity, we explored the impact of smoking with a range of RR CD (association of smoking and lung cancer: 6e17 for SCC, 1.5e5.0 for adenocarcinoma), which were estimated from one recent meta-analysis. 22 Furthermore, we addressed the potentially differential relation by sex. The relative risk of 11.98 for males and 8.97 for females for smoking-SCC association, and the relative risk of 3.55 for males and 2.32 for females for smoking-adenocarcinoma association were used as the best guess for RR CD . 22 
Results
During the period from January 1, 2000 to December 31, 2000, a total of 640,173 patients were initially identified by the algorithm and 596,812 patients were included in the analysis (Fig. 1 ). These patients were followed for a median of 7.9 years. Meanwhile, a total of 174,800 (27.3%) patients died, whereas only 1566 (0.2%) were lost to follow-up due to discontinuation from or drop-out of health insurance.
In the diabetic cohort, 270,564 (45%) patients had ever received statins. The most commonly prescribed statin in terms of cumulative usage was atorvastatin (29.7%), followed by simvastatin (20.6%), lovastatin (17.7%), fluvastatin (12.7%), pravastatin (10.8%), and rosuvastatin (8.4%). Because the NHI treatment guideline on dyslipidemia requests that patients attaining the targeted goal of cholesterol reduction either discontinued or titrated down to the minimal dosage of statin therapy, the mean cumulative duration was 590 days among the statin users during the study period.
A total of 60,969 statin users and 535,843 statin nonusers were identified in the diabetic cohort in 2000. As compared with statin nonusers, statin users were more likely to be female, at low socioeconomic status, and have cardiovascular disease, cerebrovascular disease, diabetic long-term complications, or chronic kidney disease. Statins users were also more likely to receive metformin, glinides, a-glucosidase inhibitors, insulin, antihypertensive agents, aspirin, and fibrates during the 12-month period before the initiation of statin therapy (Table 1) .
Lung cancer risk in statin users estimated from the NHI claims database
A total of 1182 incident lung SCC cases and 2345 lung adenocarcinoma cases were identified. In the univariate analyses, use of statin as a class was found to have a negative association with SCC incidence, but not for adenocarcinoma. After controlling for potential confounding variables, a significantly decreased risk of SCC incidence was found for statin use at any time (HR, 0.69; 95% CI, 0.60e0.81; Table 2 ). The protective effects were evident for high and intermediate cumulative dosage and for cumulative treatment duration 1 year, 1e2 years, and 2e3 years with a potential durationeresponse relationship. Risk estimates were similar between prevalent and newlydiagnosed type 2 diabetes patients, prevalent and new statin users, and different sex and age groups ( Table 3) . No association was found for any use of statin and adenocarcinoma (HR, 0.97; 95% CI, 0.88e1.07), or in any of the dose and duration category ( Table 2 ).
In the analysis examining the lung cancer risk of individual statin, pravastatin (HR, 0.64; 95% CI, 0.45e0.90), lovastatin (HR, 0.74; 95% CI, 0.58e0.95), and atorvastatin (HR, 0.78; 95% CI, 0.63e0.97) were associated with a significantly reduced risk of SCC (Table 4 ). The number of cancer cases exposed to individual statin was too small to allow us to further evaluate the potential doseeresponse and durationeresponse relationships.
Sensitivity analysis
Among the 27,726 participants that completed the NHIS, there were 1073 individuals who had a physician-confirmed diagnosis of diabetes and were aged 30 years or older. Of the 376 participants with complete records on lipidlowering medications and smoking history, the proportion of smokers among statin users and nonusers was 24% and 35%, separately. For lung SCC (RR CD of 6e15) and given the observed relation of 0.69 for statin as a class and 0.64 for pravastatin, the fully adjusted RR would be 0.86e0.94 and 0.80e0.87, individually. Considering a specific RR CD of 11.98 for males and 8.97 for females, the fully adjusted RR would be 0.92 for males and 0.90 for females for statin as a class. For lung adenocarcinoma (RR CD of 1.5e5.0) and given the observed relation of 0.97 for statin as a class and 1.02 for pravastatin, the fully adjusted RR would be 1.02e1.19 and 1.07e1.25, separately. Given a specific RR CD of 3.55 for males and 2.32 for females, the corresponding adjusted RR would be 1.14 for males and 1.08 for females for statin as a class (Fig. 2 ).
Discussion
The results of this study demonstrate that statin use was not associated with occurrence of lung adenocarcinoma. However, the seemingly negative association between statin use and SCC incidence is mostly attributed to a lower incidence of smoking in those taking statin.
Diabetes has been linked with an increased risk of cancer occurrence. 13, 14 Statin is widely used in diabetic patients; however, its effect on cancer incidence has not been determined. Therefore, it is important to explore the risk of statin associated with cancer in this vulnerable population. Our findings of a neutral association between statin and lung cancer were comparable to those of recent reports. Two large-scale studies demonstrated that long-term use of statin is not associated with overall cancer or lung cancer incidence. 23, 24 Also, two meta-analyses of observational studies found no association between statin use and risk of lung cancer. 25, 26 However, there are still controversies concerning this association. A cohort study conducted in northern California showed an increased risk of lung cancer in women, which could be partially attributable to their smoking habits. 27 Reciprocally, other US studies reported a reduction in the risk of lung cancer. 7,28 Apart from the abovementioned time-window bias and immortal time bias, smoking information is not uniformly collected in healthcare databases or medical records and accordingly its strong confounding effect was not fully adjusted for in the cohorts and caseecontrol studies. 29, 30 Recently, due to the multifaceted approach to cardiovascular prevention, statin use may be accompanied by an effort of smoking cessation. Therefore, the observed protective effect of statin on reducing lung cancer might be attributed to and confounded by a concomitant reduction in smoking, as demonstrated in our sensitivity analysis. A caseecontrol study analyzing the Taiwan NHI database reported a non-significantly decreased risk of lung cancer for statin (adjusted odds ratio, 0.82; 95% CI, 0.58e1.15). 31 Compared with our study, it did not manage the residual confounding of smoking using external information. In addition, it restricted to female populations and examined the relationship with overall lung cancer rather than individual cancer types. This may explain its slightly inconsistent findings with our results. Furthermore, it is known that the relationship of smoking and lung cancer varies with cancer types, with a higher risk for SCC than for adenocarcinoma. 22 Therefore, the confounding effect of smoking will be more profound for SCC than for adenocarcinoma. This may partially illustrate why the protective effect of statin is observed on SCC rather than on adenocarcinoma prior to when we performed the sensitivity analysis.
Besides the residual confounding effect by smoking, other factors that may explain the putative association between statin use and lung cancer occurrence reported by previous studies include body mass index (BMI), concomitant care, and detection bias. Furthermore, patients undergoing statin therapy may have higher socioeconomic status and receive a better quality of care. They may take more frequent preventive health services such as chest X-ray examinations which lead to a different chance of lung cancer detection as compared with nonusers. 32 However, in our study, the BMI (mean AE standard deviation, kg/m 2 ) did not apparently differ between statin users (26.4 AE 3.9) and nonusers (25.5 AE 4.3) based on information in the NHI program. Also, no substantial difference in socioeconomic status (using monthly income as a proxy) was found among statin treatment groups, probably because the universal NHI program covers all Taiwanese people regardless of income level. Another concern is that most statin users are those who had cardiovascular or cerebrovascular diseases and thus were at increased risk of death due to these comorbidities such that competing risk may play a role in the observed protective association. However, we adjusted for confounding effects of comorbidities through the regression model, which may partially minimize the impact of competing risk on the observed negative association.
The universal and compulsory NHI program in Taiwan offered the strength of low loss to follow-up rate in this study. The highly accurate information on cancer occurrence and pathology verified by linkage through National Cancer Registry allowed us to examine the association with SCC and adenocarcinoma separately. Moreover, we used time-varying instead of time-fixed analysis to reduce potential immortal time bias. There are limitations in this study. First, the information of several potential confounding factors, such as smoking, BMI, and physical activities, cannot be obtained from the healthcare claims database. Although we did adjust for some of major factors and use sensitivity analysis to explore the "true" association, residual confounding effect could possibly exist. Second, we did not explore the mechanistic background of the pleiotropic effect of statins. Numerous laboratory studies suggest that statins might inhibit lung cancer growth, but the results from clinical trials are discouraging. 33, 34 Finally, as the mean daily dosage among the study patients was relatively low due to low persistency rate on statin therapy, our findings would probably not generalize to the risk associated with higher dosage of statin use for a longer treatment duration.
In conclusion, there is no statistically significant association between statin use and lung adenocarcinoma in the diabetic patients in Taiwan. The negative association between statins and SCC could be largely attributed to the confounding effect of cigarette smoking. This result has demonstrated the importance of fully adjusting for the confounding effect of smoking when the association between statin use and lung cancer is explored from largescale healthcare databases as a cohort or a case-control study. 
